Study identifier:16008
ClinicalTrials.gov identifier:NCT02540668
EudraCT identifier:N/A
CTIS identifier:N/A
Effect of LY3314814 on the Pharmacokinetics of Warfarin in Healthy Subjects
Healthy
Phase 1
Yes
Lanabecestat, Warfarin
All
15
Interventional
18 Years - 65 Years
Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 Oct 2019 by AstraZeneca
AstraZeneca
Eli Lilly and Company
The purpose of this study is to look at how much warfarin gets into the blood stream and how long it takes the body to get rid of it when given both with and without lanabecestat. Another purpose is to evaluate the effectiveness of warfarin therapy to prevent blood clots when given with lanabecestat by measuring international normalized ratio (INR). INR measures the time it takes for blood to clot and compares it to an average. Information about any side effects that may occur will also be collected. The study will last about 5 weeks from the first dose to follow-up for each participant.
Location
Location
Evansville, IN, United States, 47710
Arms | Assigned Interventions |
---|---|
Experimental: Warfarin Single oral dose of 15 mg warfarin on Day 1. | Drug: Warfarin Administered orally |
Experimental: Lanabecestat + Warfarin Lanabecestat administered orally once daily on Days 8 to 27, with a single oral dose of 15 mg warfarin co-administered on Day 22. | Drug: Lanabecestat Administered orally Other Name: LY3314814 Other Name: AZD3293 Drug: Warfarin Administered orally |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.